bms561392 and Hepatitis--Autoimmune

bms561392 has been researched along with Hepatitis--Autoimmune* in 1 studies

Other Studies

1 other study(ies) available for bms561392 and Hepatitis--Autoimmune

ArticleYear
Selective inhibition of tumor necrosis factor-α converting enzyme attenuates liver toxicity in a murine model of concanavalin A induced auto-immune hepatitis.
    International immunopharmacology, 2013, Volume: 17, Issue:2

    Emerging evidence suggest that tumor necrosis factor (TNF)-α plays a major role in pathogenesis of auto-immune hepatitis (AIH) induced liver injury. Blockade of TNF-α synthesis or bio-activity protects against experimental AIH. TNF-α converting enzyme (TACE) is a member of the ADAM (a disintegrin and metalloproteinase) family which processes precursor TNF-α to release soluble TNF-α. We hypothesized that selective inhibition of TACE might protect AIH. To investigate this, we studied the effects of a selective TACE inhibitor DPC-333 on murine model of liver injury and fibrosis induced with concanavalin A (Con A). Pre-treatment with DPC-333 significantly suppressed plasma alanine transaminase, aspartate transaminase and cytokines such as TNF-α, interferon (IFN)-γ, interleukin (IL)-2 and IL-6 levels due to acute Con A challenge. Interestingly; DPC-333 inhibited liver poly (ADP-ribose) polymerase (PARP)-1 activity which was associated with reduced number of necrotic hepatocytes in histological examination and mortality associated with Con A. In fibrosis study, repeated Con A administration significantly up-regulated liver collagen deposition as assessed by measurement of hydroxyproline content which was further confirmed in liver histology with Masson's trichrome staining. Treatment with 30mg/kg of DPC-333 was able to suppress liver hydroxyproline and fibrous tissue proliferation which corroborated well with inhibition in expression of pro-fibrotic genes such as tissue inhibitor of metalloproteinase (TIMP)-1 and transforming growth factor (TGF)-β1. These observations suggest that selective TACE inhibition is an effective approach for the treatment of both immune mediated hepatic inflammation and fibrosis.

    Topics: ADAM Proteins; ADAM17 Protein; Alanine Transaminase; Animals; Aspartate Aminotransferases; Cells, Cultured; Concanavalin A; Cytokines; Disease Models, Animal; Down-Regulation; Fibrosis; Hepatitis, Autoimmune; Hepatocytes; Inflammation Mediators; Liver; Mice; Mice, Inbred BALB C; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinolines; Tissue Inhibitor of Metalloproteinase-1; Transcriptional Activation

2013